Trial Profile
A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin, in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Doxorubicin liposomal (Primary) ; Mirvetuximab soravtansine (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms FORWARD II
- Sponsors ImmunoGen
- 01 Feb 2023 Results evaluating the antitumor activity and safety profile of the combination of mirvetuximab soravtansine and bevacizumab in patients with platinum-resistant ovarian cancer, published in the Gynecologic Oncology
- 29 Sep 2022 Results presented in an ImmunoGen Media Release.
- 29 Sep 2022 According to an ImmunoGen media release, data will be presented at the 2022 International Gynecologic Cancer Society (IGCS) Annual Global Meeting.